T he Affordable Care Act (ACA) expanded Medicaid eligibility to nonelderly citizens and permanent residents with incomes below 138% of the federal poverty level in participating states. As of September 2018, 33 states and Washington, DC, had adopted Medicaid expansion, while 17 states had not. 1 These expansions have been associated with improved coverage, access to care, preventive care, and in some studies, self-rated health. [2] [3] [4] [5] Research examining Medicaid's effects on physical health outcomes has yielded conflicting findings. A randomized trial of Medicaid coverage in Oregon failed to detect statistically significant 2-year changes in glycosylated hemoglobin, blood pressure, or cholesterol levels, 6 while 2 studies reported significant declines in mortality following Medicaid expansions in the early 2000s and Massachusetts health reform in 2006. 7, 8 Some policy observers have cited uncertainty about the effects of insurance to claim that the ACA could be scaled back without serious health consequences. 9 Most studies on the ACA have focused on population-wide changes in health outcomes; however, expanded coverage may disproportionately affect populations with serious chronic illnesses. Compared with the general population, persons with endstage renal disease (ESRD) experience increased morbidity and mortality, lost productivity, and impaired quality of life.
10 Access to effective predialysis care can improve survival, but many patients receive little or no nephrology care before starting dialysis. 10,11 Furthermore, although Medicare provides insurance to most patients requiring dialysis, coverage does not typically begin until the fourth month of dialysis. 12 Prior to
Medicaid expansion, up to one-fifth of nonelderly patients lacked insurance coverage when initiating dialysis. 10, 13 Being uninsured is associated with inadequate access to recommended predialysis care, underdiagnosis of diabetes and hypertension (the 2 leading causes of ESRD), and undertreatment of cardiovascular disease. [13] [14] [15] This study examined the association of the ACA Medicaid expansions with mortality, insurance coverage, and predialysis nephrology care for patients with ESRD initiating dialysis.
Methods

Study Design
Brown University's institutional review board and the Centers for Medicare & Medicaid Services (CMS) Privacy Board approved the study protocol and waived the need for informed consent. We conducted a difference-in-differences study that examined changes in outcomes among new dialysis patients in states that expanded Medicaid eligibility under the ACA compared with changes among patients in nonexpansion states. The study period extended from January 1, 2011, to March 31, 2017. We defined the postexpansion period for each state based on its own implementation date (eAppendix in the Supplement).
Data Sources and Study Population
We obtained data from the CMS Renal Management Information System (REMIS). Incident patients were identified from the ESRD Medical Evidence Form (CMS 2728), which is included in the REMIS data (eAppendix in the Supplement) The CMS 2728 form provides evidence of a diagnosis of ESRD for Medicare eligibility and "demographic and diagnostic information for all new ESRD patients regardless of Medicare entitlement."
16 CMS requires the form to be completed for all newly diagnosed patients with ESRD at the time of receiving the first maintenance dialysis treatment or transplant, including those who do not have current Medicare coverage and those who do not anticipate applying for future Medicare coverage. The form is not collected for patients with acute kidney injury who are treated with dialysis. Information on timing and cause of death was obtained from the ESRD Death Notification (CMS 2746). CMS requires that the dialysis facility last responsible for a patient's maintenance dialysis submit the form within 2 weeks of the date of death.
The study population included all US patients aged 19 to 64 years who initiated dialysis (either hemodialysis or peritoneal dialysis) during the study period, with the exception of 69 529 patients with Medicare coverage (without Medicaid), 40 758 patients with dual Medicare-Medicaid coverage, and 4125 patients with Veterans Affairs (VA) coverage without Medicare. Sensitivity analyses included those with Medicare and VA coverage. Further descriptions of the outcomes and number of patients for secondary outcomes are provided in the eAppendix, eFigure 1, and eTable 1 in the Supplement.
Measures
The primary outcome was whether a patient died during a 1-year period beginning with the 91st day following the initiation of dialysis. This approach is consistent with that used by the US Renal Data System because deaths among incident patients are not reliably reported within the first 90 days following dialysis initiation.
were limited to patients starting hemodialysis. The primary independent variable was an interaction between residing in a Medicaid expansion state and initiating dialysis after that state expanded Medicaid.
Covariates included age, sex, race/ethnicity (nonHispanic white, non-Hispanic black, Hispanic, or other) as reported in REMIS data, primary cause of ESRD (diabetes, hypertension, or other), comorbid conditions, current smoking, alcohol dependence, hemoglobin level, serum albumin level, body mass index, and proportion of persons living in the patient's census tract or zip code with income below the federal poverty level. The dialysis facility collected and reported information on race/ethnicity using fixed categories in the CMS 2728 form. Race/ethnicity was included in the study to adjust for changes in the demographic composition of states over time and to conduct stratified analyses of the association of expansion with health outcomes. To obtain information on area-level poverty, patients' residential addresses were geocoded to census tracts using ArcGIS spatial mapping software, version 10.5.1 (ESRI). The 2009-2013 American Community Survey provided the poverty rate in each patient's census tract. For 13.2% of patients who could not be geocoded to a census tract but for whom zip codes were available, we used zip code-level poverty as measured in the 2010 US Census.
Statistical Analysis
We constructed multivariable generalized linear regression models with Huber-White robust standard errors clustered at the state level to account for the state-level correlation and potential serial autocorrelation. 18 All models included state and year-month fixed effects and specified a binomial outcome distribution with identity link function. For observations with missing covariates, we used the mean value of the covariates on the nonmissing observations. Further descriptions of the regression specification and alternative approaches to handling missing data are described in the eAppendix in the Supplement. Exploratory subgroup analyses by age, race/ethnicity, and area-level poverty rates tested the significance of 3-way interactions among expansion status, postexpansion time period, and each aforementioned subgroup. Similarly, interactions between state and postexpansion time period yielded state-level adjusted changes. The number needed to treat (NNT), defined as the absolute change in insurance coverage divided by the absolute change in 1-year mortality, was calculated.
Sensitivity Analyses
The following analyses assessed the validity of the difference-in-differences study design and tested the sensitivity of the estimates to alternative study populations and time periods. First, an analysis confirmed that pre-ACA outcomes were parallel in expansion and nonexpansion states by testing the significance of an expansion-by-time indicator for the pre-2014 data. Second, to examine whether the composition of patients with end-stage renal disease changed differentially after expansion (ie, whether coverage expansion was associated with a change in which patients initiated dialysis, and how far along in their disease trajectory), additional difference-in-differences models estimated the following outcomes: the log of the number of incident patients, prevalence of comorbid conditions, peritoneal dialysis rates, 19 
Results
Study Population
The Primary End Point Figure 1 plots unadjusted trends in mortality by expansion status. Mortality rates were similar in expansion and nonexpansion states prior to 2014 and then diverged, with declines in mortality rates beginning in the first 6 months of 2014. In Medicaid expansion states, 1-year mortality following dialysis initiation declined from 6.9% in the preexpansion period to 6.1% after expansion (change, −0.8 percentage points; 95% CI, −1.1 to −0.5). In nonexpansion states, mortality rates were 7.0% before expansion and 6.8% after expansion (change, −0.2 percentage points; 95% CI, −0.5 to 0.2), yielding an adjusted absolute reduction in mortality in expansion states of −0.6 percentage points (95% CI, −1.0 to −0.2) and a relative mortality reduction of 8.5% ( Table 2 ; see eTable 2 in the Supplement for unadjusted estimates). These difference-in-differences estimates were similar with and without multivariable adjustment.
Unadjusted trends in 1-year mortality rates by age, race, and area-level poverty are shown in eFigure 2 in the Supplement. Table 3 shows adjusted difference-in-differences estimates for mortality by subgroup. Adults aged 19 to 44 years experienced larger reductions in 1-year mortality (−1.1 percentage points; 95% CI, −2.1 to −0.3) than those aged 45 to 64 years (−0.5 percentage points; 95% CI, −0.9 to −0.1; P =. 01 for interaction). There were larger declines in 1-year mortality following Medicaid expansion among black patients (−1.4 percentage points; 95% CI, −2.2 to −0.7) compared with white patients (−0.5 percentage points; 95% CI, −1.2 to 0.2; P = .04 for interaction). Adjusted mortality changes were not statistically different for Hispanic patients compared with white patients or for patients living in areas with poverty rates above vs below the median area-level poverty rate, with the median level defined by the distribution in the study population. Access to predialysis nephrology care in expansion and nonexpansion states is shown in eFigure 3A in the Supplement. Rates of initiating dialysis with an arteriovenous fistula or graft present remained stable in expansion states but declined after 2014 in nonexpansion states (eFigure 3B). In adjusted analyses, Medicaid expansion was associated with a 10.5-percentage-point (95% CI, 7.7-13.2) increase in Medicaid coverage and a −4.2-percentage-point (95% CI, −6.0 to −2.3) decrease in being uninsured at the time of dialysis initiation relative to nonexpansion states (Table 2 ). There was a concurrent 1.0-percentage-point (95% CI, −0.1 to 2.1) increase in the proportion receiving care from a nephrologist prior to dialysis initiation and a 2.3-percentage-point (95% CI, 0.6-4.1) increase in initiating dialysis with a graft or fistula present. eTable 3 in the Supplement presents subgroup estimates for the secondary outcomes. Hispanic patients had increased gains in Medicaid coverage (18.5 percentage points) compared with white patients (7.6 percentage points; <.001 for interaction). Patients living in areas of higher poverty had greater increases in Medicaid coverage (11.9 percentage points) and declines in uninsurance (−5.5 percentage points) than those living in areas with lower poverty (9.1-percentage-point increase in Medicaid [P = .003 for interaction]; −3.0-percentage-point change in uninsurance [P = .004 for interaction]). Persons aged 19 to 44 years experienced larger declines in uninsurance (−6.4 percentage points) than those aged 45 to 64 years (−3.3 percentage points; P = .002 for interaction). There was no differential changes in access to predialysis nephrology care or presence of an arteriovenous fistula or graft by age (P = .77 for interaction for predialysis nephrology care; P = .08 for interaction for arteriovenous fistula or graft), race/ethnicity (P = .44 [black patients] and P = .18 [Hispanic patients] for interactions for predialysis nephrology care; P = .42 [black patients] and P =. 1 5 [Hispanic patients] for interactions for arteriovenous fistula or graft), or area-level poverty (P = .27 for interaction for predialysis nephrology care; P = .95 for interaction for arteriovenous fistula or graft). Persons aged 19 to 44 years, black patients, and those living in areas with higher rates of poverty experienced significant increases in predialysis nephrology care, with difference-in-differences values ranging from 1.7 to 2.4 percentage points. 
Secondary End Points
Sensitivity Analyses
Sensitivity analyses that excluded early expansion states ( e F i g u r e5i nt h eSupplement), examined 1-year mortality beginning on the 43rd day after dialysis initiation, considered a 21-month transition period around expansion, and used alternative approaches to handle missing covariates yielded estimates that were consistent with those of the primary analysis (eTable 2 in the Supplement). Pre-2014 trends in outcomes for expansion and nonexpansion states did not differ significantly (eTable 4 in the Supplement). Declines in mortality were significant for causes amenable to health care and nonsignificant and close to zero for nonamenable causes, such as poisonings, homicides, and other injuries (eTable 5 in the Supplement).
Medicaid expansion was not associated with significant changes in the number of patients initiating dialysis, rates of peritoneal dialysis, or prevalence of most clinical comorbidities (eTable 6 and eFigure 6 in the Supplement). The mean estimated glomerular filtration rate at dialysis initation decreased by −0.13 mL/min (95% CI, −0.22 to −0.03 mL/min) in expansion states relative to nonexpansion states, representing a relative change of approximately 1% (eTable 6 in the Supplement). In addition, among those with Medicare or VA coverage before dialysis (who should not have been affected by expansion), there were no significant changes in mortality associated with Medicaid expansion (eTable 7 in the Supplement).
Discussion
In this national study of nonelderly adults with ESRD initiating dialysis, the ACA Medicaid expansion was associated with a significant decline in 1-year mortality, as measured by both absolute and relative reductions. The decline in death rates was concentrated among health care-amenable causes of death, consistent with prior population-level studies of health insurance expansion. 8, 20 To our knowledge, these results are the first published evidence of a significant change in mortality associated with coverage expansion under the ACA. Exploratory analyses of secondary outcomes suggest a plausible causal pathway for these findings, with Medicaid expansions associated with significant coverage gains and reductions in the use of high-risk central venous catheters without the presence of a maturing arteriovenous fistula or graft. Mortality reductions were largest among black patients and those aged 19 to 44 years, consistent with the larger gains in health insurance and nephrology care observed for those subgroups.
Although this study is not randomized, several factors suggest a causal relationship between Medicaid expansion and mortality reductions. First, mortality rates in expansion states were stable for 3 years before the ACA and then declined immediately at the time of expansion, while they remained flat The reported values in these columns refer to the 1-year mortality rate. The percentages were calculated as the percentage of patients initiating dialysis who died within 1 year beginning on the 91st day after initiation.
b Difference-in-differences estimate for each specified age, race/ethnicity, and area-level poverty rate below or greater than or equal to the median. All 95% CIs are derived from generalized linear regression models with Huber-White robust standard errors clustered at the state level.
c P value for comparison of difference-in-differences estimate with reference group. The study findings are unlikely to be explained by differential change in the characteristics or timing of patients initiating dialysis. The main results were unaffected by adjustment for an extensive set of demographic, clinical, and socioeconomic characteristics. Furthermore, expansion was not associated with clinically meaningful changes in the glomerular filtration rate at dialysis initiation or the prevalence of comorbid conditions. In addition, the number of patients initiating dialysis did not change significantly in expansion states relative to concurrent trends in nonexpansion states. This suggests that unlike more discretionary conditions, for which expanded coverage may induce more utilization, population rates of dialysis initiation are likely to be fairly consistent in the short term regardless of coverage rates.
Two previous studies of Medicaid expansions in the early 2000s and Massachusetts' 2006 health reform reported more modest declines in death rates. 7, 8 The former study estimated 1 life saved for every 239 to 316 adults gaining coverage, while the latter reported an NNT of 830 adults gaining coverage to prevent 1 death per year. In this study, the NNT to avoid 1 death within 1 year is more than an order of magnitude lower than that reported in those prior analyses. This finding likely reflects the markedly higher annual mortality rate among persons with ESRD-approximately 7% in the study population vs 0.3% (283 per 100 000) in the general Massachusetts population. Compared with white patients, black patients experienced larger coverage gains and a 3-fold greater decline in 
Limitations
This study has several limitations. First, the findings may not generalize to patients with other chronic health care conditions. Second, the expansion of insurance could alter the time course of when patients with chronic kidney disease choose to initiate dialysis, which could change the composition of the population over time; however, the sensitivity analyses demonstrated little evidence that such a change occurred. Third, the outcomes were limited to 2 measures of nephrology care and 1-year mortality. The study did not assess other health services that may improve long-term outcomes in the ESRD population, including kidney transplantation and treatment of diabetes and cardiovascular disease. Other research demonstrating increased access to prescription drug coverage after Medicaid expansion provides an additional potential mechanism for improved outcomes in the study cohort. 23 Medicaid expansion has been associated with an increase in Medicaid-covered preemptive kidney transplantations, though such transplantations remain uncommon, particularly among racial minorities and those with lower socioeconomic status. 24 Fourth, predialysis nephrology care, as measured in the REMIS data, has demonstrated poor agreement with Medicare claims. 25 The potential misclassification of this outcome would likely bias estimates toward finding no association with expansion. The measure of vascular access has been validated in a prior study.
26
Fifth, the data lacked individual-level information on eligibility for Medicaid, though it did include a robust area-level measure of poverty by geocoding residential addresses, which tracked closely with coverage gains in the study population. Sixth, it is possible that time-varying confounders that may have biased the results, though the nonsignificant changes in the Medicare and VA populations and for nonhealth care-amenable causes of death offers support for Medicaid expansion as the key factor in the observed mortality changes.
Conclusions
Among patients with ESRD initiating dialysis, living in a state that expanded Medicaid under the ACA was associated with lower 1-year mortality. If this association is causal, further research is needed to understand what factors may have contributed to this finding. 
eAppendix. Supplementary Methods and Results
Section 1. Definition of Expansion and Nonexpansion States and Post Period
Patients were designated as undergoing dialysis in an expansion state if they resided in an expansion state as of the time they initiated dialysis. The table below provides a list of expansion states, their date of Medicaid expansion, and whether they were also designated as an early expansion state for sensitivity analyses described in Section 4. 
Expansion and Nonexpansion States and Date of Expansion
Section 3. Regression Specification
For each outcome Y, we estimated the following multivariate regression: (1) where denotes individual, s denotes state of residence at the time a patient initiated dialysis, and m denotes the year and month when the patient initiated dialysis. Here s is a vector of state level indicators, and m is a vector of indicator variables indicating the period (year month) when a patient first initiated dialysis. Further, Xis is a vector of covariates and includes the following variables: age (in years), sex, race/ethnicity (non Hispanic white, non Hispanic black, Hispanic, other), primary cause of ESRD (diabetes, hypertension, other), comorbid conditions, current smoking, alcohol dependence, hemoglobin level (g/dl), serum albumin (g/dl), body mass index (kg/m2), and the proportion of persons living in the patient's Census Tract or ZIP Code with income below the federal poverty limit. The variable Expandism is an indicator variable that equals 1 if an individual initiated dialysis in an expansion state after that state expanded Medicaid, and equals 0 otherwise. 1 is the main coefficient of interest and represents the adjusted mean difference between expansion and Nonexpansion states in the change in outcomes from the pre expansion period to the post expansion period.
Section 4. Parallel Trends Assumption
Our difference in difference specification assumes that, if Medicaid expansion had not occurred, the outcomes would have trended similarly across expansion and Nonexpansion states. Therefore, we attribute observed post policy divergence in the outcomes to the impact of the ACA Medicaid expansions rather than a pre policy difference in trends. We investigated this parallel trends assumption underlying our empirical model by estimating an equation similar to equation (1) using only pre policy data. The model included an interaction between whether or not a state expanded Medicaid and a linear year month specific time trend.
Section 5. Sensitivity Analyses
We explore the robustness of our mortality estimates to alternate specifications. The results of the sensitivity analyses are presented in eTable 2. 1 In eFigure 5, panels A E, we present graphs of our main outcomes after dropping these early expansion states.
Accounting for Early Expansion
Alternative Approach to Handling Missing Data
In our study population, the rate of missing was 5% for body mass index (BMI), 14% for hemoglobin, 2% for area level poverty, and 30% for serum albumin. Our first method to address the missing data for each variable was to assume that the data was missing at random, replacing the missing observation with the mean value for the non missing observations, and including an indicator variable if the observation had a missing value. Although simple to implement, this approach suffers from the problem of introducing errors in the correlation between variables, thereby also potentially biasing the estimated coefficients. The problem is most severe for albumin for which about 30% of the observations have missing values. We therefore also used a multiple imputation approach to account for missing values of albumin. This approach leverages the potential correlation of albumin with other variables such as age, gender, and co morbidities. Using these variables, we imputed a value for albumin and do this 20 times to generate 20 different estimates of imputed albumin. The STATA procedure combines the point estimates derived from all imputations to arrive at a single point estimate and associated confidence interval. In eTable 2, we explore the sensitivity of our mortality estimate to using multiple imputation for missing values for albumin.
Excluding Transitional Periods Around Medicaid Expansion
Patients who started dialysis in an expansion state prior to 2014 may have acquired Medicaid coverage through the expansion after 2014. We therefore examined the sensitivity of our mortality estimates after excluding all patients living in expansion states who initiated dialysis during the fifteen month period prior to expansion. Further, the health effects of Medicaid expansion may take time to materialize. Therefore, we conducted a second sensitivity analysis that excluded the six month period immediately following the implementation date in each expansion state.
Consideration of One year Mortality Beginning on the 43 rd day Following Initiation of Dialysis
Our primary outcome was one year mortality beginning on the 91 st day following initiation of dialysis. This approch is consistent with that used by the United States Renal Data System, because deaths in the early period following dialysis initiation are undercounted in the REMIS data.
2,3 Given a recent paper that determined that undercounting of deaths are concentrated in the first 6 weeks following initiation, 3 we examined the sensitivity of our estimates after defining one year mortality beginning on the 43 rd day following the initiation of dialysis.
Examining Mortality Amenable and Not Amenable to Health Care
Using data on the cause of death information provided in form CMS 2746, we classified deaths that were not amenable to healthcare as those due to a drug overdose, accident unrelated to treatment, or suicide. As with our primary outcome of all cause mortality, we required the death to have occurred within 1 year following the 91 st day after initiating dialysis. Similarly, we constructed an indicator variable to measure mortality amenable to health care, by excluding deaths that were due to drug overdose, accident unrelated to treatment, or suicide.
Assessing Changes in Clinical Severity Post Expansion
It is also possible that the expansion of insurance could alter the timecourse of when patients with chronic kidney disease choose to initiate dialysis, which could change the composition of the study population over time. To investigate this, we examined differential changes in the number of patients, type of initial dialysis, and prevalence of comorbid conditions in expansion vs. nonexpansion states. Specifically, we constructed generated difference in difference estimates for the log of the number of incident patients, the proportion initiating peritoneal dialysis, the estimated glomerular filtration rate, and the prevalence of the seven comorbid conditions listed in Table 1 of the main paper.
Estimation of Difference in Differences for Persons with Medicare, VA and Dual Medicare Medicaid Coverage
In our primary analysis, we excluded patients with Medicare, dual Medicare Medicaid, or VA coverage, since the ACA's expansion did not change Medicaid eligibility for these patients.
As a falsification test, we determined whether Medicaid expansion was associated with changes in outcomes for these populations. In one model, we combined Medicare (n=69,529) and VA (n=4,125) patients given the relatively small number in the latter group. The other model included patients with dual Medicare Medicaid coverage (n=40,758). eTable 7 shows the difference in difference estimates and associated p values for each of these sub groups of patients. We find that Medicaid expansion was not associated with significant changes in mortality for these subgroups. Notes: Coefficient presented is 1 from equation (1). The regression includes the same set of covariates as that included in our main model ( Table 2 ). In addition, since the Medicare/VA column combines data from both the Medicare and VA patients, this specification also includes an indicator variable for VA coverage.
eFigure 1. Study Population Flowchart
